Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Baxter
Harvard Business School
McKesson
Mallinckrodt

Last Updated: August 14, 2022

Investigational Drug Information for QGC001


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for QGC001?

QGC001 is an investigational drug.

There have been 10 clinical trials for QGC001. The most recent clinical trial was a Phase 2 trial, which was initiated on June 25th 2020.

The most common disease conditions in clinical trials are Hypertension, Essential Hypertension, and Myocardial Infarction. The leading clinical trial sponsors are Quantum Genomics SA, Eurofins Optimed, and PRA Health Sciences.

There are three US patents protecting this investigational drug and forty-seven international patents.

Recent Clinical Trials for QGC001
TitleSponsorPhase
Randomized Study of Extended Treatment With Firibastat in Treatment-Resistant Hypertension (REFRESH)PRA Health SciencesPhase 3
Randomized Study of Extended Treatment With Firibastat in Treatment-Resistant Hypertension (REFRESH)Quantum Genomics SAPhase 3
Firibastat in Treatment-resistant HypertensionQuantum Genomics SAPhase 3

See all QGC001 clinical trials

Clinical Trial Summary for QGC001

Top disease conditions for QGC001
Top clinical trial sponsors for QGC001

See all QGC001 clinical trials

US Patents for QGC001

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
QGC001 See Plans and Pricing Derivatives of 4,4'-dithiobis-(3-aminobutane-1-sulfonates) and compositions comprising the same Institute National de la Sante et de la Recherche Medicale (Inserm) (Paris Cedex, FR) See Plans and Pricing
QGC001 See Plans and Pricing Method for the preparation of (3S, 3S') 4,4'-disulfanediylbis (3-aminobutane 1-sulfonic acid) QUANTUM GENOMICS (Paris, FR) See Plans and Pricing
QGC001 See Plans and Pricing Method for the preparation of (3S,3S') 4,4'-disulfanediylbis (3-aminobutane 1-sulfonic acid) QUANTUM GENOMICS (Massy, FR) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for QGC001

Drugname Country Document Number Estimated Expiration Related US Patent
QGC001 Austria AT455097 2023-08-06 See Plans and Pricing
QGC001 Canada CA2533432 2023-08-06 See Plans and Pricing
QGC001 Cyprus CY1109950 2023-08-06 See Plans and Pricing
QGC001 Germany DE602004025119 2023-08-06 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Baxter
Harvard Business School
McKesson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.